Aerolase launches US FDA-approved Neo Elite laser treatment in collaboration with Kaya

IMT News Desk
IMT News Desk
· 2 min read

The treatment will now be available across all Kaya clinics nationwide

Aerolase, a technology leader in laser skin health, has taken a significant step forward in the Indian market with the launch of its US FDA-approved Neo Elite laser treatment in collaboration with Kaya, a dermatology chain clinic in India. The treatment will now be available across all Kaya clinics nationwide.

Madhusudhan HK, Country Manager, Aerolase.  India’s dermatology and aesthetic market is among the fastest-growing globally, projected to grow The device effectively addresses active acne, post-inflammatory hyperpigmentation, and redness in the same session, minimising the need for multiple treatments. Its versatility means it can treat a range of concerns, from teenage Acne to adult acne and postpartum breakouts, and can be safely integrated with existing skincare routines.”

Nishant Nayyar, Marketing Head and VP, shared, “The Neo Elite’s laser, which is exclusive amongst all chain clinics in India offers a safer, effective solution for all skin types, including sensitive, with no downtime.”

Dr Priya Puja, Head Dermatologist (North & East), Kaya Clinic, said, “This technology allows us to offer highly effective, non-invasive treatments that are gentle on sensitive and all skin tones, something that conventional therapies often fall short of.”

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk